Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.

@article{Machuca2017MortalityAW,
  title={Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.},
  author={Isabel Machuca and Bel{\'e}n Guti{\'e}rrez-Guti{\'e}rrez and Irene Gracia-Ahufinger and Francisco Rivera Espinar and {\'A}ngela Cano and Julia Guzm{\'a}n-Puche and Elena P{\'e}rez-Nadales and Clara N{\'a}tera and Marina Rodr{\'i}guez and Rafael Le{\'o}n and Juan Jos{\'e} Cast{\'o}n and Fernando Rodr{\'i}guez-L{\'o}pez and Jes{\'u}s Rodr{\'i}guez-Ba{\~n}o and Juli{\'a}n Torre-Cisneros},
  journal={Antimicrobial agents and chemotherapy},
  year={2017},
  volume={61 8}
}
Combination therapy including colistin and a carbapenem has been found to be associated with lower mortality in the treatment of bloodstream infections (BSI) due to KPC-producing Klebsiella pneumoniae when the isolates show a meropenem or imipenem MIC of <16 mg/liter. However, the optimal treatment of BSI caused by colistin- and high-level carbapenem… CONTINUE READING